Inogen (NASDAQ:INGN) Shares Cross Below Two Hundred Day Moving Average – What’s Next?

Shares of Inogen, Inc (NASDAQ:INGN) passed below its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of $7.03 and traded as low as $6.19. Inogen shares last traded at $6.19, with a volume of 169,003 shares trading hands.

Analysts Set New Price Targets

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of Inogen in a report on Monday, December 22nd. One analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $11.00.

Inogen Stock Down 4.8%

The stock has a market capitalization of $168.55 million, a P/E ratio of -7.20 and a beta of 1.77. The company has a fifty day moving average price of $6.06 and a 200-day moving average price of $7.03.

Inogen (NASDAQ:INGN) last released its quarterly earnings results on Tuesday, February 24th. The medical technology company reported ($0.26) earnings per share for the quarter, beating the consensus estimate of ($0.36) by $0.10. The business had revenue of $81.72 million during the quarter, compared to analysts’ expectations of $82.00 million. Inogen had a negative return on equity of 11.56% and a negative net margin of 6.52%. As a group, research analysts expect that Inogen, Inc will post -1.73 earnings per share for the current fiscal year.

Institutional Trading of Inogen

A number of large investors have recently made changes to their positions in the business. Alliancebernstein L.P. grew its position in Inogen by 3.9% in the third quarter. Alliancebernstein L.P. now owns 51,120 shares of the medical technology company’s stock worth $418,000 after acquiring an additional 1,900 shares in the last quarter. Russell Investments Group Ltd. lifted its position in Inogen by 14.6% in the fourth quarter. Russell Investments Group Ltd. now owns 19,543 shares of the medical technology company’s stock worth $131,000 after buying an additional 2,487 shares during the last quarter. Rhumbline Advisers lifted its position in Inogen by 7.0% in the second quarter. Rhumbline Advisers now owns 39,059 shares of the medical technology company’s stock worth $275,000 after buying an additional 2,561 shares during the last quarter. American Century Companies Inc. boosted its stake in Inogen by 4.9% during the second quarter. American Century Companies Inc. now owns 61,238 shares of the medical technology company’s stock worth $431,000 after buying an additional 2,858 shares during the period. Finally, Barclays PLC boosted its stake in Inogen by 4.5% during the fourth quarter. Barclays PLC now owns 81,980 shares of the medical technology company’s stock worth $551,000 after buying an additional 3,515 shares during the period. 89.94% of the stock is currently owned by institutional investors.

About Inogen

Inogen, Inc (NASDAQ: INGN) is a medical device company specializing in the development, manufacture and marketing of innovative oxygen therapy solutions. The company’s core focus is on portable oxygen concentrators (POCs) designed to support patients with chronic respiratory conditions such as chronic obstructive pulmonary disease (COPD). Inogen’s offerings aim to provide users with mobility and independence by reducing reliance on traditional compressed-gas cylinders and enabling oxygen therapy on the go.

Inogen’s flagship product line, including the Inogen One family of portable oxygen concentrators, leverages proprietary flow technology to deliver continuous and pulse-dose oxygen.